Myosin Therapeutics, Inc., a clinical-stage biotechnology company developing first-in-class therapies that modulate molecular ...

Hypertrophic cardiomyopathy (HCM) is the most common hereditary heart disease. It causes the left ventricle to thicken, the ...

The FDA has granted fast track designation to MT-125 for the treatment of patients with glioblastoma. The U.S. Food and Drug ...

MT-125, a dual small-molecule inhibitor, received FDA fast track designation for glioblastoma, facilitating expedited drug ...

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) is one of the best small cap stocks with the highest upside. H.C. Wainwright ...

Maintaining a good level of physical fitness is important. However, it can be difficult to determine what fitness entails.

During the development of hypertrophy, cardiac myocytes increase organization of the sarcomere, a highly ordered contractile unit in striated muscle cells. Several hypertrophic agonists, such as ...

Event-native data platform innovator Kurrent today announced the release of KurrentDB 25.1, delivering its most developer-friendly event sourcing database yet and removing traditional barriers that ...

C Spire, a leading national advanced technology company, announced today that it is recognized as one of America's Most Admired Workplaces 2026 by Newsweek and Plant-A Insights Group. This marks the ...

Bristol-Myers Squibb Company has had a recent 30% stock decline amid concerns over patent expirations. Click here to read why BMY stock is a Hold.

This valuable study investigates the role of HIF1a signaling in epicardial activation and neonatal heart regeneration in mice. Using a combination of genetic and pharmacological approaches, the ...

Cytokinetics should hear back from the FDA next September about its marketing application for aficamten, which is vying to become the first rival to Bristol-Myers Squibb's fast-growing Camzyos for ...